MIRA PHARMACEUTICALS, INC. (MIRA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US60458C1045
MIRA PHARMACEUTICALS, INC. financials
| Fiscal year | 2025 |
|---|---|
| EBIT | -10.44 m USD |
| Net income | -10.44 m USD |
| Diluted EPS – continuing operations | -1.35 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MIRA PHARMACEUTICALS, INC.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
More stocks
- ENERGY FOCUS, INC/DE (EFOI)
- RAND CAPITAL CORP (RAND)
- QS Energy, Inc. (QSEP)
- iANTHUS CAPITAL HOLDINGS, INC. (ITHUF)
- Planet 13 Holdings Inc. (PLNH)
- MILESTONE SCIENTIFIC INC. (MLSS)
- Hyperscale Data, Inc. (GPUS)
- QT IMAGING HOLDINGS, INC. (QTI)
- SPRUCE POWER HOLDING CORP (SPRU)
- CROWN CRAFTS INC (CRWS)
- SB Technology Holdings, Inc. (BIOM)
- Ankam, Inc. (ANKM)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.